MeSH tree: E01.789.800.285
Researchers from RWJBarnabas Health and Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, as well as Tufts Medical Center and The University of Manchester, have ...
Jun 20, 2025
0
22
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according ...
May 30, 2025
0
21
For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study published in the May issue of Brain and Behavior.
May 21, 2025
0
15
Results from a new Phase 3 trial published in the journal npj Precision Oncology found that a cancer stem cell test can accurately choose more effective treatments and lead to improved outcomes for patients with platinum-resistant ...
Apr 4, 2025
0
47
An international team of researchers, including experts from the University of Adelaide, has found genomic testing and targeted therapies for patients with advanced cancer could improve survival rates by up to 40%.
Apr 2, 2025
0
15
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to ...
Jan 27, 2025
0
19
For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared with preoperative chemoradiotherapy, ...
Jan 23, 2025
0
17
A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in ...
Jan 3, 2025
0
21
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative ...
Dec 13, 2024
0
24
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy—proton beam therapy or intensity modulated radiation therapy (IMRT)—achieved equally high rates of ...
Sep 30, 2024
0
29
